Skip to main content
SpringerLink
Log in

The use of long-acting octreotide improves quality of life (QOL) in patients with cancer who have loperamide-refractory diarrhoea,

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Mystakidou K, Katsouda E, Tsilika E, Smyrniotis V, Vassiliou I, Tsiatas M, Vlahos L.Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment. Anticancer Research 26: 2325-2328, No. 3, May-Jun 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The use of long-acting octreotide improves quality of life (QOL) in patients with cancer who have loperamide-refractory diarrhoea,. Pharmacoecon. Outcomes News 509, 9 (2006). https://doi.org/10.2165/00151234-200605090-00026

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605090-00026

Keywords

Search

Navigation